Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Neasa Mc Gettigan, Aman Shah Afridi, Grace Harkin, Caroline Lardner, Stephen Patchett, Danny Cheriyan, Gavin Harewood, Karen Boland, Aoibhlinn O'Toole
Summary: The study aimed to identify optimal management strategies for anti-drug antibodies (ADAs) in patients receiving infliximab (IFX) to prevent therapy discontinuation. Results showed that increasing IFX dosage and adjusting combination therapy can lower rates of discontinuation of IFX, with significant cut-off values for ADA trough levels and important clinical outcomes identified through ROC curve analysis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Article
Gastroenterology & Hepatology
Ohad Atia, Sasha Harel, Natan Ledderman, Shira Greenfeld, Revital Kariv, Iris Dotan, Ran Balicer, Barbara Silverman, Eran Matz, Zohar Levi, Matti Waterman, Iris Fried, Jacob M. Rowe, Dan Turner
Summary: Pediatric onset inflammatory bowel disease (PIBD) patients have a higher risk of developing cancer compared to non-inflammatory bowel disease (IBD) children, but the absolute risk is very low, and no significant differences in risk were found among different treatment methods in our data.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Immunology
Yiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, Mi Jin Kim
Summary: This study found that patients with high monocyte counts at the time of discontinuation were more likely to experience relapse after stopping biologics. The monocyte percentage can be used to predict the risk of relapse within 6 months after discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Adam Truong, Karen N. Zaghiyan, James Mirocha, Gil Y. Melmed, Dermot P. B. McGovern, Gaurav Syal, Christina Y. Ha, Stephan R. Targan, Phillip R. Fleshner
Summary: This study found that preoperative TNFi use may increase the risk of developing de novo CD after IPAA, while older age is a protective factor.
COLORECTAL DISEASE
(2021)
Article
Biology
Kacper Nijakowski, Piotr Eder, Marek Simon, Katarzyna Korybalska, Janusz Witowski, Anna Surdacka
Summary: The study found that the levels of S100A8/calprotectin, myeloperoxidase, and IgA in the saliva of patients with inflammatory bowel disease were significantly decreased. Myeloperoxidase and TNF-R1 concentrations showed high differentiation potential for distinguishing between Crohn's disease and ulcerative colitis.
Article
Gastroenterology & Hepatology
Wenhui Zhang, Astrid Scalori, Franklin Fuh, Jacqueline McBride, Gaohong She, Jaroslaw Kierkus, Bartosz Korczowksi, Regan Li, Mariam Abouhossein, Alysha Kadva, K. T. Park, Meina Tao Tang
Summary: This study evaluated the pharmacokinetics, pharmacodynamics, and safety of Etrolizumab in children with inflammatory bowel disease. The results showed that Etrolizumab was well tolerated and demonstrated clinical activity in children.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Medicine, General & Internal
Lorenzo Bertani, Brigida Barberio, Domenico Trico, Federico Zanzi, Daria Maniero, Linda Ceccarelli, Ilaria Marsilio, Francesca Coppini, Greta Lorenzon, Maria Gloria Mumolo, Fabiana Zingone, Francesco Costa, Edoardo Vincenzo Savarino
Summary: The study found that hospitalization for intravenous biologics treatment did not increase the risk of COVID-19 infection in patients with inflammatory bowel diseases during the COVID-19 outbreak. Additionally, there was a similar level of anxiety between patients receiving intravenous and subcutaneous drug treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Laura E. Targownik, Charles N. Bernstein, Eric Benchimol, Gilaad G. Kaplan, Harminder Singh, Aruni Tennakoon, Zoann Nugent, Stephanie B. Coward, M. Ellen Kuenzig, Sanjay K. Murthy
Summary: Early administration of anti-TNF therapy is associated with reduced healthcare resource utilization in CD, but not in UC.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Marla C. Dubinsky, Fernando Magro, Flavio Steinwurz, David P. Hudesman, Jami A. Kinnucan, Ryan C. Ungaro, Markus F. Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
Summary: This study found associations between C-reactive protein (CRP) and partial Mayo score (PMS) with efficacy outcomes during tofacitinib induction in patients with ulcerative colitis (UC). It also demonstrated that measurements of CRP and PMS at specific time points have predictive value for efficacy outcomes.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Jordan E. Axelrad, Terry Li, Salam P. Bachour, Takahiro Nakamura, Ravi Shah, Michael C. Sachs, Shannon Chang, David P. Hudesman, Stefan D. Holubar, Amy L. Lightner, Edward L. Barnes, Benjamin L. Cohen, Florian Rieder, Eren Esen, Feza Remzi, Miguel Regueiro, Benjamin Click
Summary: Postoperative recurrence of Crohn's disease is common after ileocecal resection. This dual-center study found that early initiation of an anti-TNF agent within 4 weeks following the surgery can reduce the risk of postoperative recurrence.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot S. Coburn, ThucNhi Tran Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan Halloran, Gursimran S. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, James Izanec, Amanda Teeple, Chris Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Dan Hogan, Samit Datta, Ryan C. Ungaro, Brigid S. Boland, Matthew Bohm, Monika Fischer, Sashidhar Sagi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana Lukin, Ellen J. Scherl, Jean-Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel Regueiro, William J. Sandborn, David Bruining, Sunanda Kane, Edward V. Loftus, Parambir S. Dulai
Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Samuel Tanner, Jeffry Katz, Fabio Cominelli, Miguel Regueiro, Gregory Cooper, Emad Mansoor
Summary: This article examines the prevalence of inflammatory bowel disease in patients with gastritis, duodenitis, and peptic ulcer disease, taking into consideration the presence of Helicobacter pylori infection. It is found that inflammatory bowel disease is less common in patients with H. pylori, and there is no increased risk of developing IBD after undergoing H. pylori eradication therapy.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Medicine, Research & Experimental
Miguel Regueiro, Theresa Hunter, Rina Lukanova, Mingyang Shan, Rosie Wild, Hannah Knight, Priyanka Bannikoppa, April N. Naegeli
Summary: This study assessed the prevalence of fatigue and its association with disease activity and patient-reported outcomes among patients with ulcerative colitis (UC) or Crohn's disease (CD). The results showed that fatigue is a common symptom among patients with UC or CD and is associated with higher disease activity levels and decreased work productivity. Managing fatigue may require a multidisciplinary approach.
ADVANCES IN THERAPY
(2023)
Article
Gastroenterology & Hepatology
Yaara Zisman-Ilani, Kimberly D. Thompson, Lori S. Siegel, Todd Mackenzie, Damara J. Crate, Joshua R. Korzenik, Gil Y. Melmed, Patricia Kozuch, Bruce E. Sands, David T. Rubin, Miguel D. Regueiro, Raymond Cross, Douglas C. Wolf, John S. Hanson, Ronald M. Schwartz, Raluca Vrabie, Michael D. Kreines, Timothy Scherer, Marla C. Dubinsky, Corey A. Siegel
Summary: This study aimed to test the impact of shared decision making (SDM) on choice of therapy, decision quality, and provider trust in patients with Crohn's disease. The results showed that patients who received the SDM intervention more frequently chose combination therapy, had lower decisional conflict, and had greater trust in their provider.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Cardiac & Cardiovascular Systems
Talha Ahmed, Konstantinos Marmagkiolis, Michelle Ploch, Jorge A. Irizarry-Caro, Atia Amatullah, Shyam Desai, Moez K. Aziz, Akshitha Yarrabothula, Jose Fossas-Espinosa, Efstratios Koutroumpakis, Saamir Hassan, Kaveh Karimzad, Peter Kim, Mehmet Cilingiroglu, Cezar Iliescu
Summary: Cardiovascular disease and cancer are leading causes of global mortality. As novel cancer therapies continue to emerge, there is an increasing population of cancer patients with cardiac complications. Accordingly, clinical studies have shifted focus towards the interdisciplinary study of oncology and cardiology. This review article provides a comprehensive overview of major articles and guidelines in the field of cardio-oncology from 2021-2022.
CURRENT PROBLEMS IN CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Kevin A. Honan, Saamir Hassan, Anita Deswal, Joerg Herrmann, Juhee Song, Dominique Monlezun, Daniel Halperin, Armeen Mahvash, Arvind Dasari, Efstratios Koutroumpakis, Mehmet Akay, Dinu-Valentin Balanescu, Ismael Salas de Armas, Manish Patel, Sriram Nathan, Biswajit Kar, Konstantinos Marmagkiolis, Juan Lopez-Mattei, Jay Patel, Igor Gregoric, James Yao, Cezar A. Iliescu
Summary: CnHD is a common cause of morbidity and mortality in patients with neuroendocrine tumors and carcinoid syndrome. Few studies have investigated the outcomes of patients after valve replacement surgery. Monitoring PV velocities with echocardiographic studies every 3 months could identify patients with occult disease that promotes valve degeneration, and novel neuroendocrine tumor therapies may have a beneficial impact on preventing valve degeneration.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Efstratios Koutroumpakis, Adam Niku, Christopher K. Black, Abdelrahman Ali, Humaira Sadaf, Juhee Song, Nicolas Palaskas, Cezar Iliescu, Jean-Bernard Durand, Syed Wamique Yusuf, Hans C. Lee, L. Maximilian Buja, Anita Deswal, Jose Banchs
Summary: This study investigated the predictive role of echocardiographic and cardiac histomorphology parameters in mortality of patients with cardiac AL amyloidosis. Patients with biopsy-proven cardiac AL amyloidosis were analyzed for myocardial strain and histomorphology. The results showed that lower LA strain and absence of SCT were associated with increased risk of death, and higher LV mass and lower RV tricuspid annular plane systolic excursion were associated with increased odds of interstitial amyloid deposition on biopsy. This study suggests the potential benefits of using LA strain in routine assessment and the positive effect of SCT in cardiac AL amyloidosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Editorial Material
Medicine, General & Internal
Rafael Luis Luporini, Pamela Cristina Bellaz Do Amaral Campos Silva, Miguel Regueiro
FRONTIERS IN MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Dominique J. Monlezun, Andrew Badalamenti, Awad Javaid, Kostas Marmagkiolis, Kevin Honan, Jin Wan Kim, Rishi Patel, Bindu Akhanti, Dan Halperin, Arvind Dasari, Efstratios Koutroumpakis, Peter Kim, Juan Lopez-Mattei, Syed Wamique Yusuf, Mehmet Cilingiroglu, Mamas A. Mamas, Igor Gregoric, James Yao, Saamir Hassan, Cezar Iliescu
Summary: This is the largest cohort study to date on valvular pathology, treatment, disparities, mortality, and cost in patients with malignant carcinoid tumor (MCT). The study found that patients with MCT had higher inpatient mortality, longer length of stay, and increased costs compared to those without MCT. Additionally, the study found an increasing rate of TVR and PVR over the study period, but MCT did not significantly increase the likelihood of undergoing these valve replacements.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Jill K. J. Gaidos, Badr Al Bawardy, Francis A. Farraye, Miguel Regueiro
Summary: This study investigated the utilization rates of IBD endoscopic scoring systems in clinical practice and associated factors. The study found that the Mayo Endoscopic Subscore (MES) and the Rutgeerts Score were more commonly used, while endoscopic scores for Crohn's disease and pouchitis had lower rates of use. Regular attendance at IBD conferences, higher patient volumes, and incorporation of scoring systems into endoscopy software were associated with increased utilization of these scoring systems.
CROHNS & COLITIS 360
(2023)
Review
Cardiac & Cardiovascular Systems
Adam S. Potter, Mohit M. Hulsurkar, Lingling Wu, Bharat Narasimhan, Kaveh Karimzad, Efstratios Koutroumpakis, Nicolas Palaskas, Anita Deswal, Bharat K. Kantharia, Xander H. T. Wehrens
Summary: Recent advances in cancer treatment have provided more therapeutic options, including targeted therapies such as kinase inhibitors (KIs). However, KIs have been shown to cause various cardiovascular toxicities, with atrial fibrillation (AF) being one of the major side effects. Understanding the underlying mechanisms and managing AF in cancer patients receiving KI treatment present unique challenges.
JACC-CLINICAL ELECTROPHYSIOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Miguel Regueiro, Theresa Hunter Gibble, Alison Potts Bleakman, Xingyuan Li, Nathan Morris, William J. Eastman
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Khaled Alsabbagh Alchirazi, Ahmed Eltelbany, Abdul Mohammed, Somtochukwu Onwuzo, Miguel Regueiro
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)